May 19, 2024

U.S. parents await results as kids’ COVID-19 vaccine nears approval – National | Globalnews.ca

In an ideal world, Leah Smithers said she could afford to wait for longer-term testing of the COVID-19 vaccines before getting the jab for her 10-year-old son.

But with his juvenile diabetes putting him at greater risk of complications if he contracts the virus – and with so much of his young life already shaped by the pandemic – she is ready for him to receive the vaccine as soon as he is eligible.

“I’m a parent who is concerned about the food I put in their bodies, about anything I put in their bodies,” said Smithers, 43, who lives in the San Francisco suburb of Albany and has two other children, ages 13 and four. “But this seems like the best choice to keep him safe.”

Read more:
Pfizer Canada eyeing urgent COVID-19 vaccine approval for children aged 5 to 11

Story continues below advertisement

Monday’s announcement from Pfizer and BioNTech that a low dose of their coronavirus vaccine proved safe and effective for children ages five to 11 in a clinical trial has come as a relief to many parents anxiously awaiting the chance to protect their children.

The highly contagious Delta variant of the virus has collided with the start of the U.S. academic year, sending infections among young children soaring – including many cases requiring hospitalization – and forcing thousands of schools to shut for days or even weeks.

The companies said they plan to file for regulatory authorization as soon as possible for a 10-microgram dose for children ages five to 11 after it led to a strong immune response in a 2,268-participant trial. The vaccine at its original 30-microgram strength is already approved on an emergency basis for children 12 to 15. Health officials believe that the lower dose could be approved for younger children by the end of October.


Click to play video: 'Pfizer says their vaccine works for children 5-11'







Pfizer says their vaccine works for children 5-11


Pfizer says their vaccine works for children 5-11

Some parents have expressed hesitancy about the vaccine for their young children, citing the lack of large-scale studies and long-term data on its effects on that population. There are around 29 million U.S. children ages five to 11.

Story continues below advertisement

“Many are parents who themselves have been vaccinated – and their kids are vaccinated for everything else – but are just concerned about a brand-new vaccine,” said Shen Nagel, a pediatrician in the Denver area. “They also have the mindset that children are at lower risk of serious disease.”

About four in 10 parents of children ages five to 11 said they would “wait and see” how the vaccine worked before giving it to their kids, according to polling data published by the Kaiser Family Foundation in August. One-quarter said they would “definitely not” get their children vaccinated, while another quarter said they would do so “right away.”

Read more:
B.C. preparing to offer COVID-19 vaccine to 6- to 11-year-olds once approved

In interviews, pediatricians and public health experts said parents appear to be growing less hesitant as time goes on.

Nancy Lataitis, another pediatrician in the Denver area, said some pandemic-weary parents have realized that vaccination may be the only way to avoid school disruptions.

“Schools are imposing quarantines, closing down,” she said. “They’re hearing about teachers who got sick.”

Jill Goldstein, 50, had to pull her eight-year-old daughter from her New York City elementary school on the second day of the school year after another child tested positive, triggering a mandatory 10-day quarantine for the class.

Story continues below advertisement

Goldstein said she would get her daughter vaccinated but acknowledged she might not be “first in line.”

“I just want to make sure the benefit outweighs the risk,” she said. “I understand the benefit is not just for her but for the community, and I’m taking that into account as well.”

Los Angeles, home to the nation’s second largest school district, has already mandated vaccines for students 12 and up.

Slightly more than 50 per cent of U.S. children ages 12 to 15 have gotten at least one shot, according to federal data, lower than any other eligible age group.

While children remain at lower risk, close to 500 have died from COVID-19, putting it in the top-10 causes of pediatric deaths, said Sean O’Leary, vice chair of the American Academy of Pediatrics’ infectious diseases committee.

Story continues below advertisement


Click to play video: 'Pfizer and Moderna COVID-19 vaccines receive full approval along with new brand names'







Pfizer and Moderna COVID-19 vaccines receive full approval along with new brand names


Pfizer and Moderna COVID-19 vaccines receive full approval along with new brand names

In some areas with high rates of infection, pediatric hospitals have been overwhelmed.

O’Leary said there is no reason to expect the vaccine to pose any particular risk for younger children.

“These vaccines have probably been evaluated for safety better than any other medicine in history,” he said. He noted that vaccines historically do not carry long-term side effects. Adverse reactions tend to occur soon after vaccination, not months later.

It remains possible that the vaccine could cause some rare side effects in children that cannot be detected in a relatively small study. But that is not a reason to avoid vaccines, said Arthur Reingold, chair of epidemiology at the University of California-Berkeley School of Public Health.

“People say, ‘I’d like more follow-up…I want more study,’” he said. “It’s all logical and rational – and a completely impossible thing to ask for.”

Story continues below advertisement

Read more:
COVID-19 vaccine effective in children ages 5 to 11, Pfizer says

Adrienne Day, a journalist in Brooklyn, definitely plans to vaccinate her seven-year-old daughter, saying she trusts the science behind it.

“To me,” she said, “it’s just like getting the measles, mumps and rubella vaccine or the flu shot.”

(Reporting by Joseph Ax and Sharon Bernstein; Additional reporting by Jason Lange; Editing by Colleen Jenkins and Bill Berkrot)





Source link